ArticleMedicine2026
Lymphocyte count and systemic immune-inflammation index (SII) as novel biomarkers for cognitive impairment: A cross-sectional study analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of cognitive dysfunction through reliable biomarkers remains a critical challenge in geriatric medicine. While conventional peripheral blood parameters offer convenient and cost-effective biomarker potential, previous studies have been limited by their focus on isolated cell populations. This study investigates both individual blood cell parameters and their derived ratios to comprehensively evaluate their relationship with cognitive function. In this cross-sectional conducted from 2022 to 2024, we enrolled 109 participants (51 with cognitive impairment and 58 controls) from the Haikou City Community Health Service Center. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). We analyzed 26 blood parameters, including traditional metrics and calculated indices such as lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index (SII). The relationship between these parameters and cognitive domains was evaluated using comprehensive statistical analyses. Fifteen parameters showed significant differences between groups. Binary logistic regression identified SII as a risk factor (OR: 1.008, 95% CI: 1.003-1.012, P = .002). The receiver operating characteristic curve analysis indicated that the diagnostic accuracy of SII (AUC = 0.911, 95% CI: 0.856-0.966) was significantly superior to that of the sole parameter, the number of lymphocyte count (AUC = 0.702, 95% CI: 0.604-0.801). Our findings suggest that lower lymphocyte counts and elevated SII levels are associated with increased risk of cognitive impairment. These results provide new insights into the relationship between systemic inflammation and cognitive decline, with potential implications for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.